A Hybrid Closed-loop Insulin Delivery System for the Treatment of Type I Diabetes

Abstract

Because their bodies no longer produce enough insulin, people with type 1 diabetes mellitus must check their blood glucose — or blood sugar — levels several times a day and then calculate and inject an appropriate insulin dosage. Wearable systems, sometimes referred to as an “artificial pancreas,” are now available to replicate some of the functions of the pancreas in controlling insulin delivery. The MiniMed 670G is currently the only hybrid closed-loop system licensed for commercial use. Available evidence supports the safety of the MiniMed 670G system for individuals with type 1 diabetes who are 14 years of age and older. Several further studies are underway, including a study in children and a larger randomized controlled trial. The manufacturer, Medtronic, expects the MiniMed 670G will be available in the US in the spring of 2017. Its availability in Canada is not yet known.